**MedTech AI Inc.**

**Symbol: Private**

**Market Cap: N/A**

**Sector: Medical Technology**

**Purpose: Financing**

MedTech AI Inc. (“MedTech” or the “Company”) is a Canadian, private funding and strategic partner which has entered into an agreement with Oxford Immune Algorithmics (“OIA”), a UK-based medical technology to acquire 38% of OIA.

Under the terms of the agreement, at such time as OIA becomes listed for trading on a recognized stock exchange (anticipated to occur by Q3 2022), MedTech shareholders will exchange their MedTech shares for pro-rata shares of OIA, the publicly listed company.

**Investor Bullet Points:**

* OIA’s UK-based team are world-leading experts in AI, Computer Science, Physics and Microelectronics, associated with both Oxford and Cambridge Universities
* OIA Founder & CEO, Dr. Hector Zenil, has published over 100 papers on the subject and helped to develop the factual answering AI engine behind both Siri and Alexa
* OIA has been working with the National Health Services in the UK (NHS) and has been approved for the commercial release of Algocyte scheduled for early 2022.  The MedTech investment in OIA will fund the Algocyte release
* Algocyte, a portable blood analyzer, is the first Artificial Intelligence-driven solution for diagnostic andpredictive health monitoring of the body's immune system including testing for antibodies
* Algocyte is an early warning device for immune-related blood diseases such as leukemia, various blood cancers, bacterial infection, heart disease, COVID-19 and other viruses
* Algocyte is patent-protected and approved for distribution in Europe, having acquired CE Marker status.
* Distribution agreements have been signed with companies in the UK, Germany, EU, USA, the Middle East, Africa and China
* MedTech’s management team, comprised of experienced international finance and operations executives, will assist OIA in financing, marketing and operations rollout
* It is anticipated that OIA will become listed for trading on a recognized stock exchange by Q3 2022
* MedTech has entered into a letter of intent with OIA to form Algocyte Canada, with MedTech owning 70% of the company
* Algocyte Canada will have the Canadian rights to Algocyte
* Algocyte Canada will seek a listing on a recognized stock exchange by the end of 2022

**Scott Young, Vice President, Corporate Development**

Scott has an extensive background in corporate development, fundraising strategy and tactical planning. Companies he has successfully helped fund are in diverse industries such as biotech, medtech and natural resources.  He has a comprehensive institutional financing network that spans North and South America, Europe and Asia. He has delivered investment results for various private or public entities. His track record of delivering value has been consistent for over 2 decades.